NCT02099747已完成3 期
A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients.
European Society for Blood and Marrow Transplantation32 个研究点 分布在 6 个国家目标入组 202 人开始时间: 2015年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 202
- 试验地点
- 32
- 主要终点
- CR rate
研究概览
简要总结
The null hypothesis of no difference in CR% at 3 months between the arms will be tested against the alternative of a difference in CR% at an alpha level of .05 by assessing the odds ratio for arm yielded by this model.
详细描述
This is a superiority trial aiming to increase the 3 month complete response rate. The sample size is calculated on the hypothesis that the experimental treatment will increase the 3 months response rate up to 21% (by 3 folds, based on the 7% reported in Scheinberg et al [17]). Under these assumptions, the sample size to reject the null hypothesis is n=96 patients for each treatment arm, increased by 4% for possibly not evaluable patients (total number of 200 patients, 100 each treatment arm). Statistical design for sample size calculation: increase from 7% (control arm) to 21% (investigational arm) in 3 month complete response rate (two-sided binomial test); alpha-error 0.05; power 0.8.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of severe or very severe aplastic anemia, defined by [29]:
- •At least two of the following:
- •Absolute neutrophil counts <0.5 x 109/L (severe) or <0.2 x 109/L (very severe)
- •Platelet counts <20 x 109/L
- •Reticulocyte counts <60 x 109/L
- •Hypocellular bone marrow (<30% cellularity), without evidences of fibrosis or malignant cells
- •Male or female age > 14 years;
- •Written informed consent
- •Willing and able to comply with all of the requirements and visits in the protocol
- •Understands that they can be randomised to either treatment arm
- •Negative pregnancy test for women of child bearing age
- •Written acceptance to use contraception (hormonal or barrier method of birth control; abstinence) for the entire duration of study participation.
排除标准
- •Prior immunosuppressive therapy with ATG (horse of rabbit) or any other lymphocyte depleting agent (i.e., alemtuzumab)
- •Eligibility to a sibling allogeneic stem cell transplantation
- •Evidence of a myelodysplastic syndrome, defined by the presence of myelodysplastic features, excess of blasts or karyotypic abnormalities typical of MDS (according to revised WHO 2008 criteria) [30],, as well as other primitive marrow disease. Patients with diagnosis of AA with cytogenetic abnormalities which are recurrent in MDS (according to revised WHO 2008 criteria) [30] should be included in this category, and are not eligible for the study; patients with del(20q), +8 and -Y are not included in this category, and thus are eligible for this study. The list of karyotypic abnormalities which qualifies for the diagnosis of MDS are listed in the Appendix.
- •History or clinical suspect of constitutional aplastic anemia (i.e. Fanconi Anemia with positive DEB/MMC test or Dyskeratosis Congenita)
- •History of malignant tumors with active disease within 5 years from enrollment, and/or previous chemo-radiotherapy
- •Previous history of stem cell transplantation
- •Treatment with cyclosporin A unless
- •<4 weeks of cyclosporin A treatment before enrolement and
- •wash out period of 2 weeks before enrollment
- •CMV viremia, as defined by positive PCR or pp65 test
- •WHO performance status ≥3
- •Pregnant or breast feeding patients
- •Patients with hepatic, renal or cardiac failure, or any other life- threatening concurrent disease
- •Patients with HIV infection
- •Patients without social health care assistance
- •Participation in another clinical trial within 1 month before the start of this trial
- •Patients and/or female partners of male patients not using highly effective method of birth control i.e. intrauterine device (IUD), hormonal (oral pill, injection, implants), tubal ligation or partner's vasectomy
- •subjects with known hypersensitivity to any of the component medications
- •The presence of a Paroxysmal Nocturnal Hemoglobinuria clone is not an exclusion criterion.
研究组 & 干预措施
hATG + CsA
Active Comparator
Control Arm
干预措施: hATG (Drug)
hATG + CsA + Eltrombopag
Experimental
Experimental
干预措施: CsA (Drug)
hATG + CsA + Eltrombopag
Experimental
Experimental
干预措施: Eltrombopag (Drug)
hATG + CsA
Active Comparator
Control Arm
干预措施: CsA (Drug)
hATG + CsA + Eltrombopag
Experimental
Experimental
干预措施: hATG (Drug)
结局指标
主要结局
CR rate
时间窗: 3 months
The primary objective of this trial is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated AA patient.
次要结局
- Overall survival(2 year)
- Event-free survival(2 year)
- Rate of CsA-independent hematological response at 24 months(2 year)
- Cumulative incidence of response(2 year)
- Heamatological Response at 6, 12, 18 and 24 months(2 year)
- Cumulative incidences of clonal evolution(2 year)
- Time to best heamatological response(2 year)
- Cumulative incidence of PNH population occurrence and clinical hemolytic PNH occurrence(2 year)
- Cumulative incidence of relapse rate(2 year)
- Cumulative incidence of discontinuation of immunosuppressive therapy(2 year)
- Comparison of number of SAEs between the two arms(2 year)
- Need for transfusions and number of transfusions required from treatment(2 year)
- Need for any supportive care(2 year)
研究者
研究点 (32)
Loading locations...
相似试验
已完成
2 期
Favipiravir in patients infected with COVID-19JPRN-jRCTs031190226Tokue Yutaka100
招募中
不适用
Randomized cross-over study comparing three models Auto-titrating positive airway pressure therapy for obstructive sleep apneamild to moderate obstructive sleep apneaobstructive sleep apneaauto-titrating positive pressure therapyAPAPTCTR20190602001department of Otorhinolaryngology62
尚未招募
2 期
Effect of Mustadi Yapana Basti Punarnavadi Ghanavati Veerataradi Ghanavati Trikantakadi Ghanavati in Chronic Kidney DiseaseCTRI/2023/02/050137Dr Ashwini Sajjanavar
已完成
不适用
A Randomised Study Comparing Laser Therapy (Greenlight XPS™ Laser System) Versus Conventional Surgery (Transurethral Resection of the Prostate [TURP]) for the Treatment of Benign Prostatic HyperplasiaISRCTN16280334American Medical Systems, Inc (USA)252
进行中（未招募）
不适用
A Comparative Study of Sexual Functions after Three Different Type of Hernia Surgery i.e. Open Mesh Hernioplasty, Laparoscopic Totally Extra Peritoneal (TEP) And Trans Abdominal Pre-Peritoneal (TAPP) RepairCTRI/2017/12/010754AIIMS